A Multimodal Approach to Diabetic Macular Edema.
10.7599/hmr.2016.36.3.151
- Author:
Joo Eun LEE
1
Author Information
1. Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. jooeun2@paik.ac.kr
- Publication Type:Review
- Keywords:
Aflibercept;
Bevacizumab;
Dexamethasone;
Diabetic Macular Edema;
Ranibizumab
- MeSH:
Adult;
Bevacizumab;
Dexamethasone;
Endothelial Growth Factors;
Humans;
Injections, Intraocular;
Intravitreal Injections;
Laser Therapy;
Light Coagulation;
Macular Edema*;
Ranibizumab;
Visual Acuity;
Vitrectomy
- From:Hanyang Medical Reviews
2016;36(3):151-154
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diabetic macular edema is one of the most common causes of visual acuity impairment in adults. Various treatment modalities are currently used. They include laser therapy, intravitreal or periocular injection of steroid, intravitreal injection of anti-vascular endothelial growth factor, and pars plana vitrectomy. Introduction of newer therapeutic agents, such as ranibizumab and aflibercept has changed the paradigm of treatment approaches for diabetic macular edema. However, traditional treatment methods, such as laser photocoagulation and vitrectomy, are still being used effectively in certain situations. Each treatment modality has its own unique mode of action, and has advantages and disadvantages at the same time. Given multiple mechanisms are involved in the development of diabetic macular edema, a combination treatment approach is often employed rather than using only one of the treatment modalities. In this review, treatment outcomes of each approach are summarized and combination approaches are discussed.
